The redemption removes a dilutive overhang but consumed most of the company's cash. Monitor subsequent filings for cash runway updates and potential need for new financing to fund operations.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $0.3950entry
- T+1 · 5d ago −9.06%α −8.71% · $0.3592
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Lakewood-Amedex redeemed all 127,097 outstanding shares of Series C Convertible Preferred Stock for $1,270,970 in cash from available funds, eliminating the potential for future dilution from conversion and leaving no preferred shares or outstanding debt. The transaction simplifies the capital structure and removes financing restrictions, but consumed a material portion of the company's cash on hand given its $1M market cap.
Key Financial Metrics
Key Facts
- Redeemed 127,097 Series C Preferred shares for $1,270,970 in cash ($10.00 per share face value)
- Redemption closed on November 4, 2026; no Series C shares remain outstanding
- Company now has no preferred stock outstanding and no outstanding indebtedness for borrowed money
- Redemption eliminates potential future dilution from conversion of Series C Preferred Stock
- Cash used for redemption was from available funds (cash on hand)
- Company has a market cap of approximately $1M
Financial Impact
Cash outflow of $1,270,970, which is approximately 127% of the company's $1M market cap, representing a significant use of available cash.
Risk Factors
- Cash used for redemption may reduce liquidity and cash runway for clinical development
- Company may need to raise additional capital, potentially causing dilution to common shareholders
- No revenue-generating products; clinical-stage biotech with ongoing cash burn
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-118127 |
| Document: ea031157601ex99-1.htm | 0001213900-26-118127 |
| Document: 0001213900-26-118127-index-headers.html | 0001213900-26-118127 |
| Document: 0001213900-26-118127-index.html | 0001213900-26-118127 |
| Document: 0001213900-26-118127.txt | 0001213900-26-118127 |
Track record
10 reports on LABT
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +88.01% at T+60 after the May 14, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bearish 7/10 Entry $0.2241 Now $0.2200 +1.83% settles Dec 16
- Nov 10, 20266d ago 8-K Neutral 4/10 Viewing Entry $0.3950 Now $0.2200 −44.30% settles Dec 10
- Sep 25, 20267w ago EFFECT Bullish 6/10 Entry $1.67 to $0.3100 Now $0.2200 −86.83% ▼ −81.44% −79.96% vs SPY
- Sep 18, 20268w ago S-1 Bearish 5/10 Entry $2.05 to $0.5834 Now $0.2200 +89.27% ▲ +71.54% +70.63% vs SPY
- Jun 17, 202621w ago 8-K Neutral 3/10 Entry $0.6022 to $0.1890 Now $0.2200 −63.47% ▼ −68.62% −68.93% vs SPY
- May 14, 202626w ago EFFECT Bearish 5/10 Entry $19.60 to $7.70 Now $0.2200 +98.88% ▲ +60.71% +59.86% vs SPY
- May 6, 202627w ago 3 Neutral 2/10 Entry $33.00 to $6.70 Now $0.2200 −99.33% ▼ −79.70% −80.51% vs SPY
- Apr 20, 202630w ago EFFECT Neutral 6/10 No price data
- Apr 1, 202632w ago S-1/A Bearish 5/10 No price data
- Mar 11, 202635w ago S-1/A Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers